Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Clinical trial NCT03672643 · TERMINATED

Trial details

NCT number: NCT03672643
Sponsor: Pfizer
Status: TERMINATED
Phase: Phase 4
Study type: INTERVENTIONAL

ALK or ROS1-positive NSCLC

Start date: 2019-01-28
Primary completion: 2023-09-28
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.